Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM)

Affiliation auteurs!!!! Error affiliation !!!!
TitreNab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM)
Type de publicationJournal Article
Year of Publication2016
AuteursHammel P, Bachet JBaptiste, Desrame J, Meurisse A, Chibaudel B, Debourdeau P, Dauba J, Lecomte T, Seitz J-Francois, Tournigand C, Aparicio T, Guerin-Meyer V, Taieb J, Volet J, Monier A, Vernerey D, Bonnetain F, Louvet C
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume34
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2016.34.15_suppl.4120